Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Winston Chan

Surgery Arlington, TX Medical Doctor

NPI 1942556485 CMS profile 2789523

1001 N Waldrop Dr Ste 802, Arlington, TX 76012

Open in the dashboard

General payments

$208,996

228 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Winston Chan of Arlington, TX is reported in the CMS Open Payments database as having received $208,996 across 228 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $18,338 29
2024 General $30,047 27
2023 General $36,665 24
2022 General $23,208 25
2021 General $11,048 16
2020 General $55,360 48
2019 General $34,330 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Winston Chan
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Winston Chan were reported at $18,338. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Winston Chan Surgery median Middle half National median
2019 $34,330 $253 $82–$1,521 $163
2020 $55,360 $131 $40–$706 $114
2021 $11,048 $168 $50–$904 $132
2022 $23,208 $224 $76–$1,218 $149
2023 $36,665 $253 $82–$1,255 $160
2024 $30,047 $279 $90–$1,381 $164
2025 $18,338 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $178,055 162 payments
  2. Ethicon Inc. $25,350 24 payments
  3. Stryker Corporation $2,293 8 payments
  4. Allergan Inc. $1,867 9 payments
  5. Davol Inc. $897 8 payments
  6. C. R. Bard, Inc. & Subsidiaries $153 1 payment
  7. AbbVie, Inc. $109 1 payment
  8. Kerecis Limited $51 3 payments
  9. Braintree Laboratories, Inc. $37 1 payment
  10. MIMEDX Group, Inc. $27 1 payment
  11. Other $158 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $154,000 39 payments
  2. Consulting Fee $25,350 24 payments
  3. Travel and Lodging $18,266 70 payments
  4. Food and Beverage $10,261 92 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,000 1 payment
  6. Gift $119 2 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $172,055 160 payments
  2. DAVINCI XI $6,000 2 payments
  3. ALLODERM $1,744 8 payments
  4. 1588 HD 3 CHIP CAMERA $967 4 payments
  5. SPY-PHI SYSTEM $731 1 payment
  6. SPY TECHNOLOGY $652 5 payments
  7. Phasix Mesh $475 4 payments
  8. INFRAVISION IMAGING SYSTEM $287 1 payment
  9. BD MAX $278 2 payments
  10. PINPOINT $150 1 payment
  11. Other $1,021 35 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

292

Median for General Surgery: 59

Drug cost

$5,495

Median for General Surgery: $393

Branded share of claims

64.4%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 48 $3,214
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 115 $1,574
Neomycin Sulfate Generic 43 $246
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 12 $161
Tramadol Hcl Generic 20 $105
Metronidazole Generic 41 $102
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 13 $92

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$98,607

Medicare's payments for the services billed

Medicare patients

202

Average age 74

Services billed

520

104 women, 98 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Diabetes 46%
Chronic kidney disease 39%
Ischemic heart disease 37%
Heart failure 32%
Depression 30%
Atrial fibrillation 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

228 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record